NCT03661437CompletedEarly phase 1
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
Light Therapy to Prevent Frailty in Older Men With Prostate Cancer on Hormonal Therapy: A Pilot RCT
Source: ClinicalTrials.gov · Last updated 11 Apr 2025
Brief summary (registry, in English)
This pilot trial studies how well systemic light exposure works in preventing frailty in older patients with prostate cancer on hormonal therapy. Hormone therapy causes many symptoms of frailty in older men including fatigue, slower time to walk a specified distance, reduced activity levels, loss of lean muscle, and muscle weakness. It is not yet known if systemic light exposure may reduce frailty in older prostate cancer patients.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- First submitted
- 5 Sept 2018
- Start date
- 24 Sept 2018
- Primary completion date
- 10 Jul 2020
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Prostate cancer
- NCT number
- NCT03661437
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 33
- From 24 Sept 2018 to the primary completion date, 10 Jul 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous use of radiation therapy within the year prior to consent.
- Previous use of light therapy to alleviate fatigue or depressive symptoms.
Other illness
- Other active malignancies
- Widely metastatic disease.
- Confounding serious medical illnesses which causes frailty.
- Severe sleep disorders.
- Eye diseases which limit the ability of light to be processed.
- Severe psychological impairment.
- Secondary cancer diagnosis within the past 5 years.
- Uncontrolled illness including ongoing or active infection in disease status patients.
Other
- Significant pre-existing frailty precluding completion of baseline assessments.
- Current employment in night shift work.
- Plans to travel across meridians during treatment.
Who the study is looking for
- Prostate cancer (PC) patients who are starting androgen deprivation therapy (ADT), abiraterone, or enzalutamide with plans to continue for at least six months with minimal evidence of disease burden in accordance with current standards of care.
- A life expectancy of 6 months or longer.
- All subjects must have the ability to understand and the willingness to sign a written or electronic informed consent.
Age in the registry: 60 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.